Continuous glucose monitoring in persons with type 2 diabetes not using insulin

References

• Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2020. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2020. Accessed 2021 Jul 20. Available at: https://www.cdc.gov/diabetes/data/statistics-report/index.html
   Google Scholar
• American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes - 2021. Diabetes Care. 2021;44(Suppl. 1):S111–S124.
   PubMedGoogle Scholar
• Kleefstra N, Hortensius J, Logtenberg SJ, et al. Self-monitoring of blood glucose in tablet-treated type 2 diabetic patients (ZODIAC). Neth J Med. 2010;68(1):311–316.
   PubMedGoogle Scholar
• Farmer A, Wade A, Goyder E, et al. Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial. BMJ. 2007;335(7611):132.
   PubMedGoogle Scholar
• MJ O, Bunting B, Copeland M, et al. Efficacy of self monitoring of blood glucose in patients with newly diagnosed type 2 diabetes (ESMON study): randomised controlled trial. BMJ. 2008;336(7654):1174–1177.
   PubMedGoogle Scholar
• Simon J, Gray A, Clarke P, et al. Cost effectiveness of self monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: economic evaluation of data from the DiGEM trial. BMJ. 2008;336(7654):1177–1180.
   PubMed Web of Science ®Google Scholar
• Kleefstra N, Hortensius J, Van Hateren KJ, et al. Self-monitoring of blood glucose in noninsulin-treated type 2 diabetes: an overview. Diabetes Metab Syndr Obes. 2009;2:155–163.
   PubMedGoogle Scholar
• 7. Diabetes technology: standards of medical care in diabetes – 2021. Diabetes Care. 2021;44(Supplement 1):S85–S99.
   PubMedGoogle Scholar
• 6. Glycemic targets: standards of medical care in diabetes – 2021. Diabetes Care. 2021;44(Supplement 1):S73–S84.
   PubMedGoogle Scholar
• Bergenstal RM, Ahmann AJ, Bailey T, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profile (AGP). Diabetes Technol Ther. 2013;15(3):198–211.
   PubMed Web of Science ®Google Scholar
• Carlson AL, Mullen DM, Bergenstal RM, et al. Clinical use of continuous glucose monitoring in adults with type 2 diabetes. Diabetes Technol Ther. 2017;19(S2):S4–s11.
   PubMed Web of Science ®Google Scholar
• Bergenstal RM. Glycemic variability and diabetes complications: does it matter? Simply put, there are better glycemic markers! Diabetes Care. 2015;38(8):1615–1621.
   PubMed Web of Science ®Google Scholar
• Hirsch IB. Glycemic variability and diabetes complications: does it matter? Of course it does! Diabetes Care. 2015;38(8):1610–1614.
   PubMed Web of Science ®Google Scholar
• Lee CL, Chen CH, Wu MJ, et al. The variability of glycated hemoglobin is associated with renal function decline in patients with type 2 diabetes. Ther Adv Chronic Dis. 2020;11:2040622319898370.
   Web of Science ®Google Scholar
• Sheng C-S, Tian J, Miao Y, et al. Prognostic significance of long-term HbA1c variability for all-cause mortality in the ACCORD trial. Diabetes Care. 2020;43(6):1185-1190.
   PubMed Web of Science ®Google Scholar
• Jang JY, Moon S, Cho S, et al. Visit-to-visit HbA1c and glucose variability and the risks of macrovascular and microvascular events in the general population. Sci Rep. 2019;9(1):1374.
   PubMedGoogle Scholar
• Guardian 3 Connect CGM System. Accessed 2021 Jul 20. Available from: https://www.medtronic.com/us-en/healthcare-professionals/products/diabetes/continuous-glucose-monitoring-systems/guardian-connect.html
   Google Scholar
• Dexcom G6 Personal CGM System. Accessed 2021 Jul 20. Available from: https://provider.dexcom.com/products/dexcom-g6-personal-cgm-system
   Google Scholar
• Eversense CGM. Accessed 2021 Jul 20. Available from: https://www.ascensiadiabetes.com/eversense/eversense-cgm-system/
   Google Scholar
• Martens T, Beck RW, Bailey R, et al. Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial. JAMA. 2021;325(22):2262-2272.
   Web of Science ®Google Scholar
• Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med. 2017;167(6):365–374.
   PubMed Web of Science ®Google Scholar
• Garg S, Zisser H, Schwartz S, et al. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care. 2006;29(1):44–50.
   PubMed Web of Science ®Google Scholar
• Bailey TS, Zisser HC, Garg SK, et al. Reduction in hemoglobin A1C with real-time continuous glucose monitoring: results from a 12-week observational study. Diabetes Technol Ther. 2007;9(3):203–210.
   PubMed Web of Science ®Google Scholar
• Yoo HJ, An HG, Park SY, et al. Use of a real time continuous glucose monitoring system as a motivational device for poorly controlled type 2 diabetes. Diabetes Res Clin Pract. 2008;82(1):73–79.
   PubMed Web of Science ®Google Scholar
• Ehrhardt NM, Chellappa M, Walker MS, et al. The effect of real-time continuous glucose monitoring on glycemic control in patients with type 2 diabetes mellitus. J Diabetes Sci Technol. 2011;5(3):668–675.
   PubMedGoogle Scholar
• Cox DJ, Banton T, Moncrief M, et al. Minimizing glucose excursions (GEM) with continuous glucose monitoring in type 2 diabetes: a randomized clinical trial. J Endocr Soc. 2020;4(11):bvaa118–bvaa.
   PubMed Web of Science ®Google Scholar
• Dixon RF, Zisser H, Layne JE, et al. A virtual type 2 diabetes clinic using continuous glucose monitoring and endocrinology visits. J Diabetes Sci Technol. 2020;14(5):908–911.
   PubMedGoogle Scholar
• Majithia AR, Kusiak CM, Armento Lee A, et al. Glycemic outcomes in adults with type 2 diabetes participating in a continuous glucose monitor–driven virtual diabetes clinic: prospective trial. J Med Internet Res. 2020;22(8):e21778.
   PubMed Web of Science ®Google Scholar
• Bergenstal RM, Layne JE, Zisser H, et al. Remote Application and Use of Real-Time Continuous Glucose Monitoring by Adults with Type 2 Diabetes in a Virtual Diabetes Clinic. Diabetes Technol Ther. 2021 Feb;23(2):128–132
   PubMed Web of Science ®Google Scholar
• Ehrhardt N, Al Zaghal E. Continuous glucose monitoring as a behavior modification tool. Clin Diabetes. 2020;38(2):126.
   PubMedGoogle Scholar
• Maurizi AR, Pozzilli P. Do we need continuous glucose monitoring in type 2 diabetes? Diabetes Metab Res Rev. 2013. DOI:https://doi.org/10.1002/dmrr.2450.
   Google Scholar
• FreeStyle Libre 2. Accessed 2020 Jul 20. Available from: https://www.freestylelibre.us/system-overview/freestyle-libre-2.html
   Google Scholar
• Hirsch IB, Wright EE Jr. Using flash continuous glucose monitoring in primary practice. Clin Diabetes. 2019;37(2):150–161.
   PubMedGoogle Scholar
• Cowart K, Updike W, Bullers K, et al. Systematic review of randomized controlled trials evaluating glycemic efficacy and patient satisfaction of intermittent-scanned continuous glucose monitoring in patients with diabetes. Diabetes Technol Ther. 2020;22(5):337-345.
   PubMed Web of Science ®Google Scholar
• Maiorino MI, Signoriello S, Maio A, et al. Effects of continuous glucose monitoring on metrics of glycemic control in diabetes: a systematic review with meta-analysis of randomized controlled trials. Diabetes Care. 2020;43(5):1146.
   PubMed Web of Science ®Google Scholar
• Haak T, Hanaire H, Ajjan R, et al. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8(1):55–73.
   PubMed Web of Science ®Google Scholar
• Ajjan RA, Jackson N, Thomson SA, et al. Reduction in HbA1c using professional flash glucose monitoring in insulin-treated type 2 diabetes patients managed in primary and secondary care settings: a pilot, multicentre, randomised controlled trial. Diab Vasc Dis Res. 2019;16(4):385–395.
   PubMed Web of Science ®Google Scholar
• Yaron M, Roitman E, Aharon-Hananel G, et al. Effect of flash glucose monitoring technology on glycemic control and treatment satisfaction in patients with type 2 diabetes. Diabetes Care. 2019;42(7):1178–1184.
   PubMed Web of Science ®Google Scholar
• Hermanns N, Ehrmann D, Schipfer M, et al. The impact of a structured education and treatment programme (FLASH) for people with diabetes using a flash sensor-based glucose monitoring system: results of a randomized controlled trial. Diabetes Res Clin Pract. 2019;150:111–121.
   PubMed Web of Science ®Google Scholar
• Wada E, Onoue T, Kobayashi T, et al. Flash glucose monitoring helps achieve better glycemic control than conventional self-monitoring of blood glucose in non-insulin-treated type 2 diabetes: a randomized controlled trial. BMJ Open Diabetes Res Care. 2020;8(1):e001115.
   PubMed Web of Science ®Google Scholar
• Miller E, Brandner L, Wright E, et al. HbA1c reduction after initiation of the freeStyle libre system in type 2 diabetes patients on long-acting insulin or noninsulin therapy. 80th Scientific Session of the American Diabetes Association. 2020. Accessed 2021 Jul 20. Available from: https://plan.core-apps.com/tristar_ada20/abstract/ca8ef3dc-0272-44cc-91dc-a59578dc9ddb
   Google Scholar
• Wright E, Kerr M, Reyes I, et al. HbA1c reduction associated with a freeStyle libre system in people with type 2 diabetes not on bolus insulin therapy. 80th Scientific Session of the American Diabetes Association. 2020. Accessed 2021 Jul 20. Available from: https://plan.core-apps.com/tristar_ada20/abstract/f66f0979-68aa-483b-8bb3-0653e5dd0473
   Google Scholar
• Peek ME, Thomas CC. Broadening access to continuous glucose monitoring for patients with type 2 diabetes. JAMA. 2021;325(22):2255–2257.
   PubMed Web of Science ®Google Scholar
• SV E, Wood R, Roberts M, et al. Patients with type 2 diabetes are willing to do more to overcome therapeutic inertia: results from a double-blind survey. Clin Diabetes. 2020;38(3):222.
   PubMedGoogle Scholar
• Chun JH, O’Neill MS. Optimizing diabetes care with the standardized continuous glucose monitoring report. Clin Diabetes. 2020;;38(2):194-200.
   Google Scholar
• Rodbard D. Continuous glucose monitoring: a review of successes, challenges, and opportunities. Diabetes Technol Ther. 2016;18(Suppl2):S3–s13. Suppl 2.
   PubMedGoogle Scholar
• Home P, Riddle M, Cefalu WT, et al. Insulin therapy in people with type 2 diabetes: opportunities and challenges? Diabetes Care. 2014;37(6):1499–1508.
   PubMed Web of Science ®Google Scholar
• Turchin A, Hosomura N, Zhang H, et al. Predictors and consequences of declining insulin therapy by individuals with type 2 diabetes. Diabetic Med. 2020;37(5):814–821.
   PubMed Web of Science ®Google Scholar
• Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2020 executive summary. Endocr Pract. 2020;26(1):107–139.
   PubMed Web of Science ®Google Scholar
• Norris SL, Lau J, Smith SJ, et al. Self-management education for adults with type 2 diabetes. Diabetes Care. 2002;25(7):1159.
   PubMed Web of Science ®Google Scholar
• Harvey JN, Lawson VL. The importance of health belief models in determining self-care behaviour in diabetes. Diabetic Med. 2009;26(1):5–13.
   PubMed Web of Science ®Google Scholar
• New JP, Ajjan R, Pfeiffer AF, et al. Continuous glucose monitoring in people with diabetes: the randomized controlled Glucose Level Awareness in Diabetes Study (GLADIS). Diabet Med. 2015 May;32(5):609–617
   PubMed Web of Science ®Google Scholar
• Vigersky RA, Fonda SJ, Chellappa M, et al. Short- and long-term effects of real-time continuous glucose monitoring in patients with type 2 diabetes. Diabetes Care. 2012 Jan;35(1):32–38. doi:https://doi.org/10.2337/dc11-1438
   Google Scholar
• Lameijer A, Fokkert MJ, Edens MA, et al. Two-year use of flash glucose monitoring is associated with sustained improvement of glycemic control and quality of life (FLARE-NL-6). BMJ Open Diabetes Res Care. 2021 Sep;9(1):e002124
   PubMed Web of Science ®Google Scholar
• Bergenstal RM, Kerr MSD, Roberts GJ, et al. Flash CGM Is Associated With Reduced Diabetes Events and Hospitalizations in Insulin-Treated Type 2 Diabetes. J Endocr Soc. 2021 Feb 2;5(4):bvab013
   Google Scholar